Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial by unknown
Spotlight on breast cancer
Travier et al. BMC Medicine  (2015) 13:121 
DOI 10.1186/s12916-015-0362-zRESEARCH ARTICLE Open AccessEffects of an 18-week exercise programme
started early during breast cancer treatment:
a randomised controlled trial
Noémie Travier1,2,3, Miranda J. Velthuis4, Charlotte N. Steins Bisschop1, Bram van den Buijs5,
Evelyn M. Monninkhof1, Frank Backx5, Maartje Los6, Frans Erdkamp7, Haiko J. Bloemendal8, Carla Rodenhuis9,
Marnix A.J. de Roos10, Marlies Verhaar11, Daan ten Bokkel Huinink12, Elsken van der Wall13, Petra H.M. Peeters1
and Anne M. May1*Abstract
Background: Exercise started shortly after breast cancer diagnosis might prevent or diminish fatigue complaints.
The Physical Activity during Cancer Treatment (PACT) study was designed to primarily examine the effects of an
18-week exercise intervention, offered in the daily clinical practice setting and starting within 6 weeks after diagnosis,
on preventing an increase in fatigue.
Methods: This multi-centre controlled trial randomly assigned 204 breast cancer patients to usual care (n = 102) or
supervised aerobic and resistance exercise (n = 102). By design, all patients received chemotherapy between baseline
and 18 weeks. Fatigue (i.e., primary outcome at 18 weeks), quality of life, anxiety, depression, and physical fitness were
measured at 18 and 36 weeks.
Results: Intention-to-treat mixed linear model analyses showed that physical fatigue increased significantly less
during cancer treatment in the intervention group compared to control (mean between-group differences at
18 weeks: −1.3; 95 % CI −2.5 to −0.1; effect size −0.30). Results for general fatigue were comparable but did not reach
statistical significance (-1.0, 95%CI -2.1; 0.1; effect size -0.23). At 18 weeks, submaximal cardiorespiratory fitness and
several muscle strength tests (leg extension and flexion) were significantly higher in the intervention group
compared to control, whereas peak oxygen uptake did not differ between groups. At 36 weeks these
differences were no longer statistically significant. Quality of life outcomes favoured the exercise group but
were not significantly different between groups.
Conclusions: A supervised 18-week exercise programme offered early in routine care during adjuvant breast
cancer treatment showed positive effects on physical fatigue, submaximal cardiorespiratory fitness, and muscle
strength. Exercise early during treatment of breast cancer can be recommended. At 36 weeks, these effects
were no longer statistically significant. This might have been caused by the control participants’ high physical
activity levels during follow-up.
Trial registration: Current Controlled Trials ISRCTN43801571, Dutch Trial Register NTR2138. Trial registered on
December 9th, 2009.
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Among the treatment-related side effects experienced by
breast cancer patients, fatigue is the most often reported
[1] and the most distressing [2]. Fatigue is reported by
up to 30 % to 60 % of cancer patients during treatment
and up to 25 % to 30 % still report fatigue many years
after treatment [3]. Recent research indicates that exer-
cise training during and after treatment may prevent
and reduce cancer-related fatigue complaints [4–7]. A
meta-analysis including studies evaluating exercise ef-
fects during adjuvant treatment for breast cancer found
a small significant reduction of fatigue following exercise
[8]. However, after excluding lower-quality studies that,
for example, did not perform intention-to-treat analyses
[9], the effect was no longer significant [8]. Recently, two
new trials, not included in said meta-analysis, offering a
12-week supervised resistance exercise intervention to
breast cancer patients, either during chemotherapy [10]
or during radiotherapy [11], reported beneficial effects
on fatigue. In both trials the control group received a
progressive muscle relaxation intervention aiming at in-
vestigating the pure physiological exercise effect isolated
from psychosocial effects. In contrast, in order to meas-
ure the effect in routine daily setting, we designed the
Physical Activity during Cancer Treatment (PACT) trial
relevant for facilitation of implementation of exercise
training into clinical care [12].
In the PACT study, the effect of an 18-week aerobic
and resistance exercise intervention was investigated.
The intervention started as early as possible after breast
cancer diagnosis and was offered at the patients’ treating
hospital. The exercise training was supervised by physio-
therapists working in daily clinical routine. The primary
outcome was fatigue at 18 weeks. Furthermore, fatigue
at 36 weeks and short- and long-term effects on second-
ary outcomes were assessed.
Methods
Setting and participants
The design of the two-arm randomised controlled PACT
study has been published elsewhere [12]. In short, the
present study was conducted in seven hospitals (one
academic and six general hospitals) in the Netherlands
between 2010 and 2013. Participants were invited by
their clinician or oncological nurse during a regular out-
patient clinic visit. The inclusion criteria were a defini-
tive full histological breast cancer diagnosis <6 weeks
before recruitment; stage M0 (i.e., no distant metastasis);
scheduled for chemotherapy (as part of the treatment
regime); aged 25 to 75 years; not treated for any cancer
in the preceding 5 years (except basal skin cancer); able
to read and understand the Dutch language; Karnovsky
Performance Status of ≥60; and no contra-indications
for physical activity. Inclusion was irrespective of thepatients’ current physical activity level. The 6-week
period was extended to 10 weeks if patients had a mast-
ectomy with immediate reconstruction involving the use
of tissue expander (n = 19). In the Netherlands, if indi-
cated, patients usually receive radiotherapy for 3 to
4.5 weeks before chemotherapy if they are at low risk of
distant metastases (less than four positive lymph nodes).
Otherwise radiotherapy is scheduled after chemotherapy.
By starting the intervention within 6 weeks post-
diagnosis, we made sure that all patients participated in
the 18-week exercise program during (part of their)
chemotherapy.
The study was approved by the Medical Ethics
Committee of the University Medical Centre Utrecht
and the local Ethical Boards of the participating hospitals
(i.e., St. Antonius Hospital, Nieuwegein; Diakonessenhuis
Hospital, Utrecht; Meander Medical Centre, Amersfoort;
Rivierenland Hospital, Tiel; Orbis Medical Centre, Sittard;
Zuwe Hofpoort Hospital, Woerden).
Breast cancer patients willing to participate were asked
to visit the study centre to confirm eligibility and sign
informed consent. A concealed computer-generated
randomisation, following a 1:1 ratio, stratified per age,
adjuvant treatment (radiotherapy yes/no before chemo-
therapy), use of tissue expander, and hospital by sequen-
tial balancing, was used to allocate participants to study
groups. Blinding of participants was not possible due to
the nature of the study, but outcome measures were
assessed by researchers not involved with the partici-
pants. Colon cancer patients were also included in the
PACT study. Results for colon cancer patients will be
presented separately to be able to address site-specific
issues. Further, results of a formal cost-effectiveness ana-
lysis will be reported elsewhere.
Intervention
An 18-week exercise programme was offered to patients
randomised to the intervention group in addition to
usual care. The programme included two aerobic and
strength exercise sessions per week, supervised by a
physiotherapist and incorporating cognitive behavioural
principles of social Bandura’s cognitive theory [13]. The
60-min exercise classes included a warming-up (5 min),
aerobic and muscle strength training (25 min each), and
a cooling down (5 min) period. The exercise program
was individualized to the patients’ preferences inventor-
ied during the first exercise session and fitness level
assessed by means of a cardiopulmonary exercise test
and 1-repetition maximum muscle strength tests.
Intensity of the aerobic training was based on the
heart rate at the ventilatory threshold as determined
during baseline cardiopulmonary exercise test. The aer-
obic training included interval training of alternating
intensity performed with a heart rate at (3 × 2 min
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to 1 × 7 min) ventilatory threshold. Heart rate and the
Borg scale of perceived exertion were monitored during
the aerobic training.
Muscle strength training was performed for all major
muscle groups: arms, legs, shoulder, and trunk. The
training started with 2 × 10 repetitions (65 % one-
repetition maximum) and gradually increased to reach
1 × 10 repetitions (75 % one-repetition maximum) and
1 × 20 repetitions (45 % one-repetition maximum) by the
end of the programme. Training intensity was re-
evaluated every four weeks by a submaximal cardiopul-
monary exercise test and by repeating the 1-repetition
maximum muscle strength tests. In addition, the partici-
pants of the intervention group were encouraged to be
physically active for at least 30 min on at least three
other days as recommended by the Dutch guidelines for
physical activity [14]. This should include an aerobic
component of moderate intensity in agreement with the
participants’ fitness and desires.
Participants randomised to control received usual care
and were asked to maintain their habitual physical activ-
ity pattern up to week 18. Then, they were allowed, for
ethical reasons, to participate in exercise programmes,
offered in the Netherlands to cancer patients after com-
pletion of primary treatment for over 10 years and are
thus part of usual care.
Outcome measures
Participants visited the study centre for outcome assess-
ment at baseline, post-intervention (18 weeks), and after
36 weeks.
Fatigue, the primary outcome (at 18 weeks), was
assessed using the Multidimensional Fatigue Inventory
(MFI) and the Fatigue Quality List (FQL). The validated
MFI is a 20-item questionnaire designed to measure
general fatigue, physical fatigue, reduced activity, re-
duced motivation, and mental fatigue [15]. Scores range
from 4 to 20, with higher scores indicating more fatigue.
The FQL consists of 28 adjectives, clustered in four sub-
scales: frustrating, exhausting, pleasant, and frightening,
addressing the perception of fatigue [16]. Participants
were asked to indicate the adjectives that fit their experi-
enced fatigue.
Quality of life (QoL) was assessed using the validated
30-item European Organisation for Research and Treat-
ment of Cancer Quality of Life Questionnaire C30 [17]
and the 36-item Short Form Health Survey (SF-36)
[18, 19]. Anxiety and depression were assessed using
the validated Dutch language version of the 20-items
Hospital Anxiety and Depression Scale [20].
Aerobic capacity was determined using a cardiopulmo-
nary exercise test with continuous breathing gas analysis.
After a 1-min warm-up at 20 W, cycling workload wasincreased every minute by a predetermined 10, 15, or
20 W until exhaustion or symptom limitation (dyspnoea
and/or fatigue). Objective criteria for exhaustion were
peak heart rate >85 % of age-predicted maximal HR, and
respiratory exchange ratio >1.10. The load for each pa-
tient was defined according to the patient’s condition in
order to reach exhaustion in about 10 min. The test was
terminated on the basis of the patient’s symptoms or at
the physician’s discretion. Peak oxygen uptake (VO2peak)
was determined by taking the mean of VO2 values of the
last 30 s before exhaustion. In addition, VO2 and power
output were assessed at ventilatory threshold [21].
Thigh muscle strength was evaluated using a Cybex
dynamometer at angular velocities of 60°/s and 180°/s.
The highest peak torque of three repetitions was calcu-
lated for both velocities and both legs.
Handgrip strength was obtained taking the best score
of two attempts provided by a mechanical handgrip
dynamometer for both hands.
Body weight and height were measured to the nearest
0.5 kg and 0.5 cm, respectively, with patients wearing
light clothes and no shoes.
Physical activity level was evaluated using the validated
Short QUestionnaire to ASsess Health enhancing phys-
ical activity (SQUASH) [22]. This questionnaire contains
questions on commuting activities, leisure-time and
sports activities, household activities, and activities at
work, and consists of three main queries: days per week,
average time per day, and intensity referring to a normal
week in the past months. We calculated the minutes per
week of moderate to high intensity total physical activity
and leisure and sport activity.
Adherence
The attendance rate for the exercise sessions and the
compliance with the protocol of the exercise sessions
were recorded in a Case Record Form. Adherence to the
exercise recommendation was recorded by the patients
in an exercise log.
Sample size calculation and statistical analysis
In order to detect a between-group change in fatigue of
2 units (±4 SD) at 18 weeks, corresponding to a medium
effect size [23], we needed 75 participants in the inter-
vention and control group (alpha = 0.05, power = 0.80)
anticipating a drop-out of 10 %. With the current num-
ber of participants (n = 204) we are even able to detect
smaller effect sizes.
Intention-to-treat mixed linear regression models were
used to model the different outcome measures at 18 and
36 weeks. These models were adjusted for baseline
values of the outcome, hospital, age, adjuvant radiother-
apy, use of tissue expander, and tumour receptor status
(triple negative/Her2Neu+, ER+ or PR+/Her2Neu+,
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group effects were modelled using outcome measure-
ments obtained at 18 and/or 36 weeks; participants with
only baseline data were not included in this analysis.
Within-group changes were modelled using outcome
measurements obtained at the three time points (i.e., at
baseline, and at 18 and/or 36 weeks) so all patients
with at least one measurement were included in this
analysis.
A sensitivity analysis was performed to assess whether
having started chemotherapy before randomisation
modified the intervention effect on fatigue. Standardized
effect sizes (ES) were calculated by dividing the adjusted
between-group difference of the post-intervention means
by the pooled baseline standard deviation. According to
Cohen, effect sizes <0.2 indicate ‘no difference’, effect
sizes of 0.2 to 0.5 indicate ‘small differences’, effect sizes
of 0.5 to 0.8 indicate ‘moderate differences’, and effect
sizes ≥0.8 indicate ‘considerable differences’ [23].
We performed per-protocol analyses among adherent
participants, i.e., excluding intervention and control partic-
ipants reporting physical activity levels, respectively, below
or above the 210 min of moderate-to-vigorous physicalFig. 1 Flow chart of the PACT randomised clinical trialactivity per week as assessed by the SQUASH question-
naire expected from participation in the intervention.
Results
Participants
Between January 2010 and December 2012, 451 breast
cancer patients were invited to participate in the study
(Fig. 1); 204 signed informed consent. The reasons for
non-participation (n = 247) were ineligibility (n = 25),
time/mental burden (n = 89), travel distance to hospital
(n = 49), problem with random assignment (n = 34), or
unknown (n = 50).
Overall, 15 of 102 participants allocated to the inter-
vention group and 25 of 102 control group participants
were lost to follow-up during the 36-week study period.
In general, participants who did not complete the
study (participants who did not come for outcome
assessment at week 36) were at baseline significantly
heavier, more fatigued, and reported more anxiety
(results not shown).
At baseline, participants in the intervention and usual
care group were comparable on most characteristics
(Table 1) except that more women in the intervention
Table 1 Baseline characteristics of the participants of the
PACT study
Intervention group Usual care group
n % n %
Education
Low 4 3.9 18 17.6
Medium 48 47.1 42 41.2
High 47 46.1 36 35.3
Unknown 3 2.9 6 5.9
Marital status
Couple 79 77.5 76 74.5
Single 20 19.6 20 19.6
Unknown 3 2.9 6 5.9
Menopausal status
Premenopausal 48 47.1 67 65.7
Postmenopausal 45 44.1 33 32.4
Unknown 9 8.8 2 2.0
Radiotherapy
No 30 29.4 33 32.4
Yes 72 70.6 69 67.6
Tissue expander
No 93 91.2 92 90.2
Yes 9 8.8 10 9.8
Her2, ER, and PR receptors
Triple negative 24 23.5 12 11.8
Her2Neu+, ER+, or PR+ 11 10.8 18 17.6
Her2Neu+, ER–, and PR– 10 9.8 2 2.0
Her2Neu–, ER+, or PR+ 57 55.9 70 68.6
Adjuvant treatment started
before recruitment
Chemotherapy 36 35.3 36 35.3
Radiotherapy 27 26.5 35 34.3
None 39 38.2 31 30.4
Mean SD Mean SD
Age (years) 49.7 8.2 49.5 7.9
Height (cm) 168.1 6.6 169.1 6.5
Weight (kg) 72.8 13.2 76.0 15.4
BMI (kg/m2) 25.8 4.4 26.6 5.2
Median IQR Median IQR
Moderate to high intensity
total PA performed before
diagnosis (min/week)*
485 240–975 600 300–1440
Moderate to high intensity
leisure and sport PA performed
before diagnosis (min/week)
180 50–375 173 60–330
IQR interquartile range, PA physical activity
* Including work, leisure, and sport activities
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ively), had triple negative breast cancer (23.5 % vs.
11.8 %), and were post-menopausal (44.1 % vs. 32.4 %).
Total physical activity levels (including activity at work)
tended to be higher in the control group, whereas
moderate-to-high leisure and sport physical activity
levels were similar in both groups.
The PACT study with a duration of 18 weeks and a
start within 6 weeks after diagnosis coincided with (all
or part of ) chemotherapy treatment in all patients; 72
patients had already started chemotherapy at recruit-
ment; 62 patients had not started chemotherapy yet, but
had started radiotherapy; and 70 patients had not started
any treatment yet, but would start with chemotherapy
early during the intervention period. Neo-adjuvant
chemotherapy was still rare, and was used in less than
5 % of PACT participants. Treatment status at baseline
was balanced between groups (Table 1).
Adherence
Patients in the intervention group showed good adher-
ence to the exercise programme: they participated in
83 % (interquartile range, 69 %–91 %) of the classes
offered. Patients reported to be physically active ac-
cording to the Dutch guideline for physical activity
in 11 (interquartile range, 6–14) of the 18 weeks.
Main outcomes
Fatigue
From pre- to post-intervention, participants in both
groups reported significant increases in fatigue (Table 2).
The increase in physical fatigue was significantly lower
in the intervention group compared to control (mean
between-group difference: −1.3; 95 % CI, −2.5 to −0.1;
ES = −0.30). Although increases in general and mental
fatigue, and in reduced activity were generally lower in
the intervention group, no significant between-group
differences were found. Over the same period, partici-
pants of both groups rated, on average to a comparable
extent, their fatigue as more frustrating and exhausting.
At 36 weeks, women reported fatigue levels and fatigue-
related feelings that were in general similar to those ob-
served at baseline with the exception of mental fatigue
in the usual care group, which was reported to be still
higher (mean: 1.0; 95 % CI, 0.1 to 1.9). No significant
differences between the exercise and the usual care
groups were found. No interaction was found between
group assignment and chemotherapy timing (P >0.05).
QoL and anxiety and depression
At 18 weeks, all participants generally reported signifi-
cant decreases in QoL and in physical, cognitive, and so-
cial functioning as well as an increase in depression
score, but none of these effects differed significantly
Table 2 Effect of exercise on fatigue based on an intention-to-treat analysis






Mean (SD) Mean [95 % CI] Mean [95 % CI] ES Mean [95 % CI] Mean [95 % CI] ES
Multidimensional Fatigue
Inventory
General fatigue UC 10.6 (4.1) 2.3 [1.4 to 3.3] Reference 0.7 [−0.3 to 1.6] Reference
I 10.1 (4.3) 1.9 [1.0 to 2.8] −1.0 [−2.1 to 0.1] −0.23 0.3 [−0.7 to 1.2] −0.9 [−2.1 to 0.3] −0.22
Physical fatigue UC 10.6 (4.1) 2.2 [1.3 to 3.2] Reference −0.4 [−1.4 to 0.6] Reference
I 9.9 (4.3) 1.6 [0.7 to 2.5] −1.3 [−2.5 to −0.1] −0.30 −0.3 [−1.3 to 0.6] −0.5 [−1.7 to 0.8] −0.11
Mental fatigue UC 10.2 (4.1) 1.5 [0.6 to 2.4] Reference 1.0 [0.1 to 1.9] Reference
I 9.8 (4.0) 1.6 [0.8 to 2.5] 0.0 [−1.2 to 1.2] 0.01 0.6 [−0.3 to 1.5] −0.6 [−1.8 to 0.7] −0.15
Reduced motivation UC 8.7 (3.4) −0.3 [−1.0 to 0.5] Reference −1.5 [−2.3 to −0.8] Reference
I 8.0 (3.5) −0.2 [−0.9 to 0.5] −0.2 [−1.1 to 0.7] −0.06 −0.6 [−1.3 to 0.1] 0.7 [−0.2 to 1.7] 0.21
Reduced activity UC 10.5 (3.7) 1.2 [0.3 to 2.1] Reference −1.1 [−2.0 to −0.2] Reference
I 10.3 (3.8) 1.0 [0.1 to 1.9] −0.4 [−1.5 to 0.8] −0.09 −1.5 [−2.3 to −0.6] −0.4 [−1.6 to 0.7] −0.11
Fatigue Quality List
Frustrating UC 22.8 (24.7) 9.8 [3.6 to 16.0] Reference 2.8 [−3.6 to 9.1] Reference
I 15.9 (19.2) 7.9 [1.9 to 13.8] −7.6 [−15.5 to 0.3] −0.34 6.0 [−0.1 to 12.1] −2.2 [−10.4 to 5.9] −0.10
Exhausting UC 6.9 (16.6) 4.9 [0.7 to 9.2] Reference −2.4 [−6.7 to 2.0] Reference
I 6.9 (15.4) 5.0 [0.9 to 9.0] 0.8 [−4.6 to 6.2] 0.05 −0.7 [−4.9 to 3.5] 2.5 [−3.1 to 8.1] 0.16
Pleasant UC 26.3 (20.7) −4.6 [−9.6 to 0.3] Reference 3.0 [−2.1 to 8.1] Reference
I 29.2 (20.6) −4.3 [−9.1 to 0.4] 2.6 [−3.2 to 8.5] 0.13 1.5 [−3.4 to 6.3] 0.5 [−5.6 to 6.6] 0.02
Frightening UC 8.8 (17.1) −1.4 [−5.0 to 2.2] Reference −4.9 [−8.6 to −1.2] Reference
I 12.5 (17.5) −3.3 [−6.7 to 0.2] 0.2 [−3.7 to 4.2] 0.01 −3.9 [−7.4 to −0.3] 2.9 [−1.2 to 7.0] 0.17
ES effect size, I intervention group, UC usual care group
Except for the pleasant dimension of the Fatigue Quality List, negative ES for fatigue dimensions indicate effects in favour of the exercise intervention group
Between-group effects were assessed using mixed models including the measurements obtained at 18 and 36 weeks, adjusted for age, hospital, radiotherapy, use
of tissue expander, receptor status and the value of the outcome variable at baseline
Within-group effects were assessed using mixed models including the measurements obtained at baseline, 18 and 36 weeks, adjusted for age, hospital, radiotherapy, use
of tissue expander, and receptor status
Baseline results and within-group differences were based on participants having baseline measurements (102 participants in each group). Between-group differences were
based on participants for whom measurements at 18 or 36 weeks were available (93 intervention and 89 usual care)
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QoL and role functioning in both groups had signifi-
cantly increased compared to baseline while cognitive
functioning had slightly decreased, but no significant dif-
ferences were observed between groups. Using the SF-36
(Additional file 1: Table S1), a significant between-group
difference was observed at 18 weeks for the item ‘change
in health’ with a difference in favour of the intervention
group (mean: 11.3; 95 % CI, 3.4 to 19.1; ES = 0.47). At
36 weeks, both groups report higher scores for mental
health, and the improvement was significantly lower in
the intervention group (mean: −4.0; 95 % CI, −7.8
to −0.1; ES = −0.26).
Physical fitness and body weight
At 18 weeks no significant between-group differences in
VO2peak and peak power output were observed. For VO2and power output at ventilatory threshold significant dif-
ferences in favour of the intervention group of 0.1 L/min
(95 % CI, 0.0 to 0.2; ES = 0.31) and 9.4 W (95 % CI, 0.5
to 18.3; ES = 0.29) were respectively observed (Table 4).
At 36 weeks, aerobic capacity did not differ between
groups.
At 18 weeks, muscle strength in the intervention
group was significantly higher for flexion and exten-
sion of both legs at 60°/s when compared to control
(ES = 0.25–0.45; Table 4). No significant differences
between groups were observed at 180°/s and for
hand grip strength. Body weight at 18 and 36 weeks
was similarly increased in both groups (Table 4).
Per-protocol analyses
Overall, 89 % of intervention participants and 56 %
of control participants reported being active with a
Table 3 Effect of exercise on quality of life, anxiety, and depression based on an intention-to-treat analysis






Mean (SD) Mean [95 % CI] Mean [95 % CI] ES Mean [95 % CI] Mean [95 % CI] ES
EORTC questionnaire
Quality of life UC 72.5 (19.4) −4.5 [−8.8 to −0.3] Reference 5.5 [1.2 to 9.9] Reference
I 74.8 (20.4) −4.4 [−8.4 to −0.4] 2.3 [−2.4 to 6.9] 0.11 4.2 [0.0 to 8.3] 0.7 [−4.1 to 5.5] 0.03
Physical functioning UC 85.0 (14.3) −5.8 [−9.1 to −2.5] Reference 0.8 [−2.5 to 4.2] Reference
I 85.3 (14.2) −4.2 [−7.3 to −1.1] 2.2 [−2.1 to 6.6] 0.16 0.4 [−2.8 to 3.6] 0.0 [−4.5 to 4.5] 0.00
Role functioning UC 69.1 (23.6) −6.7 [−12.4 to −1.0] Reference 6.1 [0.3 to 11.9] Reference
I 69.8 (23.5) −1.3 [−6.7 to 4.1] 5.9 [−1.1 to 12.9] 0.25 10.4 [4.8 to 15.9] 4.1 [−3.1 to 11.4] 0.18
Emotional functioning UC 79.2 (17.9) 2.5 [−1.0 to 6.0] Reference 4.3 [0.7 to 7.9] Reference
I 80.9 (18.2) 0.9 [−2.3 to 4.2] −0.6 [−5.3 to 4.1] −0.03 0.4 [−3.0 to 3.7] −3.0 [−7.8 to 1.9] −0.16
Cognitive functioning UC 81.7 (23.4) −7.8 [−13.1 to −2.5] Reference −6.9 [−12.3 to −1.5] Reference
I 78.8 (23.6) −10.1 [−15.1 to −5.1] −4.4 [−11.3 to 2.5] −0.19 −7.0 [−12.1 to −1.8] −2.0 [−9.2 to 5.1] −0.09
Social functioning UC 80.9 (22.2) −9.0 [−14.2 to −3.7] Reference 1.3 [−4.1 to 6.7] Reference
I 80.6 (22.0) −7.6 [−12.6 to −2.7] 1.0 [−5.3 to 7.3] 0.04 3.7 [−1.4 to 8.9] 1.3 [−5.1 to 7.8] 0.06
Fatigue UC 33.4 (23.4) 9.0 [3.9 to 14.1] Reference −1.5 [−6.7 to 3.7] Reference
I 32.2 (25.1) 7.4 [2.5 to 12.2] −3.0 [−9.1 to 3.1] −0.12 −3.9 [−8.8 to 1.1] −2.6 [−8.9 to 3.7] −0.11
Pain UC 22.9 (25.4) −0.4 [−5.7 to 4.8] Reference −0.6 [−6.0 to 4.8] Reference
I 24.0 (23.2) −3.1 [−8.1 to 1.8] −3.0 [−9.4 to 3.5] −0.12 −0.5 [−5.7 to 4.6] −0.1 [−6.7 to 6.6] 0.00
Hospital Anxiety and Depression
Scale questionnaire
Depression UC 2.4 (2.7) 1.0 [0.4 to 1.5] Reference 0.0 [−0.6 to 0.6] Reference
I 2.5 (3.1) 0.8 [0.3 to 1.3] 0.0 [−0.8 to 0.7] −0.01 0.0 [−0.5 to 0.6] 0.2 [−0.6 to 0.9] 0.06
Anxiety UC 4.2 (3.0) −0.5 [−1.1 to 0.1] Reference −0.3 [−0.9 to 0.3] Reference
I 4.4 (3.4) −0.2 [−0.8 to 0.3] 0.2 [−0.6 to 1.0] 0.06 0.2 [−0.4 to 0.8] 0.5 [−0.4 to 1.3] 0.15
ES effect size, I intervention group, UC usual care group
Negative ES for fatigue, pain, anxiety, and depression and positive ES for quality of life, physical functioning, role functioning, emotional functioning, cognitive
functioning and social functioning indicate effects in favour of the exercise intervention group
Between-group effects were assessed using mixed models including the measurements obtained at 18 and 36 weeks, adjusted for age, hospital, radiotherapy, use
of tissue expander, receptor status and the value of the outcome variable at baseline
Within-group effects were assessed using mixed models including the measurements obtained at baseline, 18 and 36 weeks, adjusted for age, hospital, radiotherapy, use
of tissue expander, and receptor status
Baseline results and within-group differences were based on participants having baseline measurements (102 participants in each group). Between-group differences were
based on participants for whom measurements at 18 or 36 weeks were available (93 intervention and 89 usual care)
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(120 min of supervised exercise and at least 30 min
of unsupervised exercise on three other days). Per-protocol
analyses showed, for both general and physical fatigue,
moderate significant differences between participants, in
both the exercise and the usual care group, who adhered
to the protocol in favour of the intervention group with ef-
fect sizes of −0.54 and −0.77, respectively (Additional file 1:
Table S2).
No serious adverse events related to exercise were ob-
served during the study period.
Discussion
The PACT study shows that an 18-week exercise inter-
vention offered in routine clinical practice and startingshortly after breast cancer diagnosis has significant
beneficial effects on physical fatigue, submaximal cardio-
respiratory fitness, and muscle strength at 18 weeks
compared to usual care. In the long-term, at 36 weeks,
when adjuvant chemotherapy was completed, fatigue
and fitness levels in both groups had returned to base-
line levels. The intervention did not significantly affect
QoL, anxiety, or depression.
The early start of our exercise intervention in breast
cancer treatment coincided with adjuvant treatment. We
therefore observed increased levels of fatigue at 18 weeks
in both groups. However, the increase in the interven-
tion group was significantly lower than for controls. The
START trial, one large study comparable to our study,
included 242 breast cancer patients receiving adjuvant
Table 4 Effect of exercise on aerobic capacity and muscle strength based on an intention-to-treat analysis






Mean (SD) Mean [95 % CI] Mean [95 % CI] ES Mean [95 % CI] Mean [95 % CI] ES
Aerobic capacity
Peak VO2 (L/min) UC 1.8 (0.3) −0.2 [−0.3 to −0.1] Reference 0.0 [0.0 to 0.1] Reference
I 1.7 (0.4) −0.2 [−0.2 to −0.1] 0.0 [−0.1 to 0.1] 0.06 0.0 [−0.1 to 0.1] −0.1 [−0.2 to 0.0] −0.20
Peak VO2/kg (mL/min/kg) UC 23.8 (5.2) −3.2 [−4.2 to −2.2] Reference 0.3 [−0.6 to 1.3] Reference
I 23.9 (5.6) −2.8 [−3.7 to −2.0] 0.5 [−0.8 to 1.7] 0.09 −0.7 [−1.6 to 0.2] −1.0 [−2.2 to 0.3] −0.18
Peak power output (Watt) UC 156.7 (34.3) −19.5 [−24.4 to-14.6] Reference 2.0 [−2.8 to 6.8] Reference
I 152.3 (38.1) −13.4 [−17.8 to −9.1] 4.0 [−2.3 to 10.4] 0.11 0.1 [−4.3 to 4.5] −3.7 [−10.1 to 2.7] −0.10
Peak heart rate (beat/min) UC 169.9 (16.6) −4.9 [−7.6 to −2.3] Reference −1.7 [−4.3 to 1.0] Reference
I 167.6 (16.7) −2.8 [−5.2 to −0.5] 0.9 [−2.7 to 4.5] 0.06 −2.2 [−4.7 to 0.2] −1.6 [−5.3 to 2.0] −0.10
VO2 at VT (L/min) UC 1.2 (0.3) −0.1 [−0.2 to 0.0] Reference 0.1 [0.0 to 0.2] Reference
I 1.2 (0.3) 0.0 [−0.1 to 0.0] 0.1 [0.0 to 0.2] 0.31 0.2 [0.1 to 0.2] 0.0 [−0.1 to 0.1] 0.12
Power output at VT (Watt) UC 82.4 (33.8) −11.5 [−18.4 to −4.6] Reference 15.7 [8.7 to 22.7] Reference
I 80.7 (31.4) −2.7 [−8.9 to 3.6] 9.4 [0.5 to 18.3] 0.29 13.7 [7.4 to 20.1] −2.0 [−11.0 to 7.0] −0.06
Muscle strength
Right knee extensor peak
torque at 60°/s (Nm)
UC 106.0 (27.3) −4.3 [−9.6 to 1.0] Reference −3.4 [−8.6 to 1.8] Reference
I 102.6 (32.0) 4.4 [−0.5 to 9.2] 7.5 [0.9 to 14.2] 0.25 0.2 [−4.7 to 5.0] 2.7 [−3.8 to 9.3] 0.09
Right knee flexor peak
torque at 60°/s (Nm)
UC 59.8 (22.7) −3.6 [−8.2 to 1.0] Reference 1.4 [−3.6 to 5.9] Reference
I 58.6 (20.5) 7.8 [3.6 to 12.0] 9.1 [3.6 to 14.6] 0.42 8.5 [4.2 to 12.8] 5.8 [0.3 to 11.2] 0.27
Left knee extensor peak
torque at 60°/s (Nm)
UC 97.7 (28.3) −4.2 [−10.6 to 2.2] Reference −4.2 [−10.4 to 1.9] Reference
I 96.4 (31.5) 6.7 [1.0 to 12.5] 9.9 [1.5 to 18.4] 0.33 2.7 [−3.1 to 8.5] 6.1 [−2.2 to 14.4] 0.20
Left knee flexor peak
torque at 60°/s (Nm)
UC 61.3 (25.3) −3.6 [−9.15 to 1.9] Reference −0.4 [−5.8 to 4.9] Reference
I 59.3 (19.7) 8.3 [3.3 to 13.3] 10.1 [3.2 to 16.9] 0.45 4.6 [−0.5 to 9.6] 2.9 [−3.8 to 9.6] 0.13
Right knee extensor peak
torque at 180°/s (Nm)
UC 58.0 (23.0) −0.3 [−5.5 to 4.9] Reference 1.9 [−3.2 to 6.9] Reference
I 54.1 (22.4) 7.4 [2.7 to 12.1] 3.6 [−2.9 to 10.2] 0.16 7.4 [2.7 to 12.2] 1.5 [−4.9 to 8.0] 0.07
Right knee flexor peak
torque at 180°/s (Nm)
UC 40.8 (20.6) 2.0 [−3.0 to 7.0] Reference 3.7 [−1.1 to 8.6] Reference
I 41.6 (20.3) 6.5 [2.0 to 11.1] 3.1 [−3.0 to 9.3] 0.15 6.7 [2.1 to 11.2] 2.2 [−3.9 to 8.2] 0.11
Left knee extensor peak
torque at 180°/s (Nm)
UC 51.0 (21.9) 0.0 [−5.4 to 5.5] Reference −0.9 [−6.2 to 4.4] Reference
I 49.1 (20.4) 5.1 [0.2 to 10.1] 3.9 [−3.2 to 10.9] 0.18 6.0 [1.1 to 11.0] 5.7 [−1.2 to 12.6] 0.27
Left knee flexor peak
torque at 180°/s (Nm)
UC 39.1 (21.2) 3.4 [−1.1 to 7.9] Reference 4.0 [−0.4 to 8.3] Reference
I 40.5 (19.1) 5.4 [1.4 to 9.5] 1.2 [−4.4 to 6.8] 0.06 6.6 [2.5 to 10.6] 2.4 [−3.1 to 7.8] 0.12
Handgrip right (kgF) UC 31.8 (5.7) −0.9 [−1.9 to 0.1] Reference −0.7 [−1.7 to 0.4] Reference
I 30.4 (5.8) −0.2 [−1.1 to 0.7] 0.1 [−1.2 to 1.5] 0.02 0.1 [−0.8 to 1.0] 0.3 [−1.1 to 1.6] 0.05
Handgrip left (kgF) UC 29.2 (6.0) −0.8 [−2.0 to 0.3] Reference 0.1 [−1.1 to 1.2] Reference
I 27.8 (5.7) 0.2 [−0.8 to 1.2] 0.8 [−0.8 to 2.3] 0.13 0.6 [−0.4 to 1.6] 0.3 [−1.3 to 1.8] 0.04
Body weight (kg) UC 76.0 (15.4) 1.5 [0.8 to 2.3] Reference 1.6 [0.8 to 2.4] Reference
I 72.8 (13.2) 1.9 [1.2 to 2.6] 0.1 [−0.9 to 1.2] 0.01 1.6 [0.9 to 2.3] −0.1 [−1.2 to 0.9] −0.01
VT ventilatory threshold, ES effect size, I intervention group, UC usual care group
Between-group effects were assessed using mixed models including the measurements obtained at 18 and 36 weeks, adjusted for age, hospital, radiotherapy, use
of tissue expander, tumour receptor status, and the value of the outcome variable at baseline
Within-group effects were assessed using mixed models including the measurements obtained at baseline, 18 and 36 weeks, adjusted for age, hospital, radiotherapy, use
of tissue expander, and tumour receptor status
Baseline results and within-group differences were based on participants having baseline measurements: body weight: 102 intervention (I) and 102 usual care
(UC), aerobic capacity: 101 (I) and 98 (UC), leg strength: 78 (I) and 79 (UC), and hand grip: 98 (I) and 100 (UC)
Between-group differences were based on participants for whom measurements at 18 or 36 weeks were available: body weight: 90 (I) and 79 (UC), aerobic
capacity: 88 (I) and 76 (UC), leg strength: 69 (I) and 64 (UC), and hand grip: 90 (I) and 79 (UC)
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Travier et al. BMC Medicine  (2015) 13:121 Page 9 of 11treatment and showed changes in fatigue, QoL, anxiety,
and depression that favoured the exercise intervention
group but results were not statistically significant [24].
A study by Mutrie et al. [25] included 203 women in a
12-week supervised group exercise programme starting
on average 6 months after diagnosis and also found non-
significant beneficial effects of the intervention on fa-
tigue and QoL. In contrast with these trials, we used a
multi-dimensional fatigue scale and found a beneficial
effect of the intervention on physical fatigue. Physical fa-
tigue might be the fatigue dimension most sensitive to
exercise. Indeed, Steindorf et al. [10] and Schmidt et al.
[11], who compared the effects of resistance exercise
and muscle relaxation on breast cancer patients’ fatigue
during adjuvant therapy, also found beneficial effects
especially on physical fatigue (ES = 0.3).
At 36 weeks, fatigue levels were back to baseline in
both groups. This lack of difference might be explained
by the fact that, from week 18, for ethical reasons,
controls were allowed to participate in exercise pro-
grammes. Nevertheless, our results show long-term fa-
tigue levels comparable across groups, and therefore it
might be worth offering exercise interventions starting
as early as possible after diagnosis to help breast cancer
patients go through one of the most distressing periods
of their life.
The non-significant changes in QoL corroborate the
results of the START study [24]. The BEATE study also
found no effect on QoL, but reported significant in-
creases in role and social functioning after a resistance
intervention offered during adjuvant chemotherapy [10].
These differences might be partly explained by the
higher baseline scores observed in the present study or
the exclusion of patients with baseline depression in the
corresponding QoL analyses in the BEATE study.
The biological mechanisms that explain the beneficial
effect of exercise on physical fatigue are not clear. Hy-
potheses include involvement in neurotoxicity of cancer
treatments, chronic stress affecting the hypothalamic-
pituitary-adrenal axis, systemic inflammatory responses,
hormonal changes, reduced anaemia, or immune activa-
tion [2]. Skeletal muscles may act as an endocrine organ
and induce myokine production associated with a re-
duced production and release of pro-inflammatory cyto-
kines [26, 27]. Furthermore, while a self-perpetuating
detraining state induces fatigue, physical training may
break this vicious cycle [28]. Additionally, psychosocial
mechanisms might play a role. Buffart et al. [29] showed
that a supervised exercise program resulted in increased
physical activity, general self-efficacy, and mastery in pa-
tients with cancer after treatment, which led to reduced
fatigue and distress and consequently improved QoL.
The PACT exercise intervention also had beneficial
effects on submaximal cardiorespiratory fitness andmuscle strength, which corroborates findings from pre-
vious studies indicating that exercise during adjuvant
treatment can prevent part of the deconditioning effect
observed during cancer treatment [24, 30, 31]. Interest-
ingly, in PACT, exercising during treatment did not only
prevent losses but improved muscle strength. The sig-
nificant results observed at submaximal level seem im-
portant since most daily activities are performed at
submaximal level.
Compared to previous related studies [10, 11, 24, 25],
the PACT study differed in the timing (i.e., early in the
treatment process) and location (i.e., at the treating
hospitals) of the intervention. In previous studies, the
intervention was mostly delivered by the same physio-
therapist(s) at a well-equipped research centre. In daily
practice, however, the intervention will be given at dif-
ferent sites with different physiotherapists. The PACT
study used this latter more pragmatic design. Although
physiotherapists worked according to a standardized
protocol the different locations may have added variabil-
ity and reduced intervention effects. However, external
generalizability is increased.
Strong features of the present study are the random-
ized design, the large sample size, and the high adher-
ence to a supervised intervention offered in different
clinical settings by different physiotherapists. Another
feature resembling daily practice is that the intervention
started within 6 weeks after diagnosis irrespective of the
start of adjuvant treatment. Although no significant
interaction was observed between group assignment and
chemotherapy timing, treatment side-effects may have
added variability to outcome measurements. The present
study also has some limitations. Participants in the
current study reported, on average, a high pre-diagnosis
physical activity level and might thus not be the ones
who needed the program most. The high level of phys-
ical activity reported by 56 % of the controls at 18 weeks
may have led to an underestimation of the true effect.
Indeed, per-protocol analyses showed that effects be-
came stronger (e.g., ES = −0.77 for physical fatigue).
However, per-protocol analyses should be interpreted
with caution because of selective non-compliance. We
offered a combined aerobic and strength exercise pro-
gram to the patients. Therefore, we cannot distinguish
what type of activity might have driven our results.
Other limitations include the fact that physical activity
was assessed by a questionnaire, as well as the relatively
low participation rate and the lack of detailed informa-
tion on patients who refused participation hampering
generalization of results.
Future directions
This study shows that exercise during adjuvant treat-
ment of breast cancer is beneficial in reducing fatigue.
Travier et al. BMC Medicine  (2015) 13:121 Page 10 of 11Women with low physical activity levels might benefit
more from exercise programs, although they might also
be less interested in participating. Future studies should
elucidate patients’ attitude, motivation, and barriers
towards participation in exercise programs in order to
specifically design exercise programs for the less active
patients.
Conclusions
The PACT trial shows that an exercise intervention of-
fered in the daily clinical practice and starting early dur-
ing adjuvant treatment is feasible and safe. The 18-week
supervised exercise intervention reduces short-term
physical fatigue and diminishment of cardiorespiratory
fitness and improves muscle strength. At 36 weeks, ef-
fects were no longer statistically significant, probably
due to participants’ high activity levels during follow-up.
Exercise is beneficial during adjuvant breast cancer treat-
ment by reducing the development of fatigue.
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of the intervention on fatigue and quality of life taking into account
compliance to study protocol.
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